Pharmacotherapy and Intensive Treatment of Drug Abuse - 1
The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders...
Brief Summary
Official Title: “Pharmacotherapy and Intensive Treatment of Drug Abuse”
The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.
- Study Type: Interventional
- Study Design: Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: Carbamazepine
Outcome Measures for this Clinical Trial
Primary Measures
- Drug use
- Effectiveness of medication
- Level of pharm
- Retention
- Depression, anxiety
Criteria for Participation in this Clinical Trial
- Please contact site for information.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 60 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: National Institute on Drug Abuse (NIDA) NIH
Overall Clinical Trial Officials and Contacts
William Haning, M.D. Principal Investigator University of Kansas
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00000217
Study ID Number: NIDA-06954-1
ClinicalTrials.gov Identifier: NCT00000217
Health Authority: United States: Federal Government
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00000217
